Bacterial Pathogens for the 1990s: A Case for New Drug Development

  • George L. Drusano


The decade of the Eighties was marked by an unprecedented acceleration in the development of new antimicrobial compounds. The early part of the decade was dominated by the introduction of multiple new beta-lactams, both extended-spectrum penicillins ( e.g. , mezlocillin, piperacillin, and azlocillin) and third-generation cephalosporins (cefotaxime, moxalactam, cefoperazone, ceftazidime, ceftizoxime, ceftriaxone, etc. ). The mid to latter part of the decade saw the introduction of carbapenem antibiotics (imipenem/cilastatin), enzyme inhibitors combined with older beta-lactams, such as ticarcillin/clavulanate and ampicillin/ sulbactam, and last, but certainly not least, fluoroquinolone antimicrobials.


Minimal Inhibitory Concentration Nosocomial Infection Xanthomonas Species Potassium Clavulanate Carbapenem Antibiotic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    al-Obeid, S., E. Collatz, and L. Gutmann. 1990. Mechanism of resistance to vancomycin in Enterococcus faecium D366 and Enterococcus faecalis A256. Antimicrob. Agents Chemother. 34:252–56.PubMedCrossRefGoogle Scholar
  2. 2.
    Bicknell, R., E.L. Emanuel, J. Gagnon, and S.G. Waley. 1985. The production and molecular properties of the zinc beta-lactamase of Pseudomonas maltophilia IID 1275. Biochem. J. 229:791–97.PubMedGoogle Scholar
  3. 3.
    Brogan, O., P.A. Garnett, and R. Brown. 1989. Bacteroides fragilis resistant to metronidazole, clindamycin and cefoxitin. J. Antimicrob. Chemother. 23:660–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Buscher, K.H., W. Cullman, W. Dick, and W. Opferkuch. 1987. Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein. Antimicrob. Agents Chemother. 31:703–08.CrossRefGoogle Scholar
  5. 5.
    Chiu, J., J. Nussbaum, S. Bozzette, J.G. Tilles, L.S. Young, J. Leedom, P.N. Heseltine, and J.A. McCutchan. 1990. Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. Ann. Intern. Med. 113:358–61.PubMedGoogle Scholar
  6. 6.
    Comick, N.A., G.J. Cuchural Jr., D.R. Snydman, N.V. Jacobus, P. Iannini, G. Hill, T. Cleary, J.P. O’Keefe, C. Pierson, and S.M. Finegold. 1987. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987. J. Antimicrob. Chemother. 25:1011–19.Google Scholar
  7. 7.
    Crane, L.R., D.P. Levine, M.J. Zervos, and G. Cummings. 1986. Bacteremia in narcotic addicts at the Detroit Medical Center. I. Microbiology, epidemiology, risk factors, and empiric therapy. Rev. Infect. Dis. 8: 364–73.PubMedCrossRefGoogle Scholar
  8. 8.
    Elting, L.S., and G.P. Bodey. 1990. Septicemia due to Xanthomonas species and non aeruginosa Pseudomonas species: increasing incidence of catheter-related infections. Medicine (Baltimore) 69: 296–306.Google Scholar
  9. 9.
    Fabbri, A., G. Marano, A. Tacchella, M.L. Belli, and C. Palmero. 1986. Susceptibility of enterococci. I. Inhibitory and bactericidal activity of several chemoantibiotics against Streptococcus faecalis and Streptococcus faecium. Chemioterapia 5:302–08.PubMedGoogle Scholar
  10. 10.
    Fasching, C.E., L.R. Peterson, J.A. Moody, L.M. Sinn, and D.N. Gerding. 1990. Treatment evaluation of experimental staphylococcal infections: comparison of betalactam, lipopeptide, and glycopeptide antimicrobial therapy. J. Lab. Clin. Med. 116:697–706.PubMedGoogle Scholar
  11. 11.
    Forrest, A., M. Weir, K.I. Plaisance, G.L. Drusano, J. Leslie, and H.C. Standiford. 1988. Relationships between renal function and disposition of oral ciprofloxacin. Antimicrob. Agents Chemother. 32:1537–40.PubMedCrossRefGoogle Scholar
  12. 12.
    Frieden, T.R., and R.J. Mangi. 1990. Inappropriate use of oral ciprofloxacin. J. Am. Med. Assoc. 264: 1438–40.CrossRefGoogle Scholar
  13. 13.
    Handwerger, S., H. Horowitz, K. Coburn, A. Kolokathis, and G.P. Wormser. 1990. Infection due to Leuconostoc species: six cases and review. Rev. Infect. Dis. 12:602–10.PubMedCrossRefGoogle Scholar
  14. 14.
    Hickey, M.M., U.M. Davies, J. Dave, M. Vogler, and R.A. Wall. 1990. Metronidazole resistant Bacteroides fragilis infection of a prosthetic hip joint. J. Infect. 20: 129–33.PubMedCrossRefGoogle Scholar
  15. 15.
    Johnson, A.P., A.H. Uttley, N. Woodford, and R.C. George. 1990. Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin. Microbiol. Rev. 3:280–91.PubMedGoogle Scholar
  16. 16.
    Lindberg, F., and S. Normack. 1986. Contribution of chromosomal beta-lactamases to beta-lactam resistance in enterobacteria. Rev. Infect. Dis. 8(Suppl. 3):S292–304.PubMedCrossRefGoogle Scholar
  17. 17.
    Lynch, M.J.; G.L. Drusano, and H.L. Mobley. 1987. Emergence of resistance to imipenem in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 31:1892–96PubMedCrossRefGoogle Scholar
  18. 18.
    Mabilat, C., S. Goussard, W. Sougakoff, R.C. Spencer, and P. Courvalin. 1990. Direct sequencing of the amplified structural gene and promoter for the extended-broad-spectrum beta-lactamese TEM-9 (RHH-1) of Klebsiella pneumoniae. Plasmid 23:27–34.PubMedCrossRefGoogle Scholar
  19. 19.
    Margaret, B.S., G.L. Drusano, and H.C. Standiford. 1989. Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 24(Suppl A):161–67.PubMedCrossRefGoogle Scholar
  20. 20.
    McGowan, J.E. Jr. 1988. Gram-positive bacteria: spread and antimicrobial resistance in university and community hospitals in the USA. J. Antimicrob. Chemother. 21(Suppl C): 49–55.PubMedCrossRefGoogle Scholar
  21. 21.
    Moellering, R.C. Jr., and A.N. Weinberg. 1971. Studies on antibiotic syngerism against enterococci. H. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. J. Clin. Invest. 50:2580–84.PubMedCrossRefGoogle Scholar
  22. 22.
    Murray, B.E. 1990. The life and times of the Enterococcus. Clin Microbiol. Rev. 3:46–65.PubMedGoogle Scholar
  23. 23.
    Mylotte, J.M., C. McDermott, and I.A. Spooner. 1987. Prospective study of 114 consecutive episodes of Staphylococcus auerus bacteremia. Rev. Infect. Dis. 9:891–907.PubMedCrossRefGoogle Scholar
  24. 24.
    Neu, H.C., G. Saha, and N.X. Chin. 1989. Resistance of Xanthomonas maltophilia to antibiotics and the effect of beta-lactamase inhibitors. Diagn. Microbiol. Infect. Dis. 12:283–85.PubMedCrossRefGoogle Scholar
  25. 25.
    O’Brien, T.F., M.P. Pla, K.H. Mayer, H. Kishi, E. Gilleece, M. Syvanen, and J.D. Hopkins. 1985. Intercontinental spread of a new antibiotic resistance gene on an epidemic plasmid. Science 230:87–88.PubMedCrossRefGoogle Scholar
  26. 26.
    Ohlsson, K., P. Bjork, M. Bergenfeldt, R. Hageman, and R.C. Thompson. 1990. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550–52.PubMedCrossRefGoogle Scholar
  27. 27.
    Oren, I., and D. Merzbach. 1990. Clinical and epidemiological significance of species identification of coagulase-negative staphylococci in a microbiological laboratory. Isr. J. Med. Sci. 26:125–28.PubMedGoogle Scholar
  28. 28.
    Patterson, J.E., and M.J. Zervos. 1990. High-level gentamicin resistance in Entero-coccus: microbiology, genetic basis, and epidemiology. Rev. Infect. Dis. 12:644–52.PubMedCrossRefGoogle Scholar
  29. 29.
    Peterson, L.R., J.N. Quick, B. Jensen, S. Homann, S. Johnson, J. Tenquist, C. Shanholtzer, R.A. Petzel, L. Sinn, and D.N. Gerding. 1990. Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S. auerus colonization. Arch. Intern. Med. 150: 2151–55.PubMedCrossRefGoogle Scholar
  30. 30.
    Phelps, D.J., D.D. Carlton, C.A. Farrell, and R.E. Kessler. 1986. Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy. Antimicrob. Agents Chemother. 29:845–48.PubMedCrossRefGoogle Scholar
  31. 31.
    Quinn, J.P., E.J. Dudek, C.A. DiVincenzo, D.A. Lucks, and S.A. Lerner. 1986. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J. Infect. Dis. 154:289–94.PubMedCrossRefGoogle Scholar
  32. 32.
    Sanders, C.C., J.P. Iaconis, G.P. Bodey, and G. Samonis. 1988. Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: Role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob. Agents Chemother. 32:1365–1369.PubMedCrossRefGoogle Scholar
  33. 33.
    Sanders, C.C., R.C. Moellering Jr., R.R. Martin, R.L. Perkins, D.G. Strike, T.D. Gootz, and W.E. Sanders Jr. 1982. Resistance to cefamandole: a collaborative study of emerging clinical problems. J. Infect. Dis. 145:118–25.PubMedCrossRefGoogle Scholar
  34. 34.
    Sanders, W.E. Jr., and C.C. Sanders. 1988. Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Rev. Infect. Dis. 10:830–38.PubMedCrossRefGoogle Scholar
  35. 35.
    Schwalbe, R.S., J.T. Stapleton, and P.H. Gilligan. 1987. Emergence of vancomycin resistance in coagulase-negative staphylococci. N. Engl. J. Med. 316:927–31.PubMedCrossRefGoogle Scholar
  36. 36.
    Sreedharan, S., M. Oram, B. Jensen, L.R. Peterson, and L.M. Fisher. 1990. DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coll. J. Bacteriol. 172:7260–62.PubMedGoogle Scholar
  37. 37.
    Trias, J., and H. Nikaido. 1990. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 34:52–57.PubMedCrossRefGoogle Scholar
  38. 38.
    Vu, H., and H. Nikaido. 1985. Role of beta-lactam hydrolysis in the mechanism of resistance of a beta-lactamase-constitutive Enterobacter cloacae strain to expanded-spectrum beta-lactams. Antimicrob. Agents Chemother. 27:393–98.PubMedCrossRefGoogle Scholar
  39. 39.
    Watanakunakorn, C. 1984. Mode of action and in-vitro activity of vancomycin. J. Antimicrob. Chemother. 14 (Suppl D): 7–18.PubMedCrossRefGoogle Scholar
  40. 40.
    Yamazaki, E., J. Ishii, K. Sato, and T. Nakae. 1989. The barrier function of the outer membrane of Pseudomonas maltophilia in the diffusion of saccharides and betalactam antibiotics. FEMS Microbiol. Lett. 51:85–89.PubMedGoogle Scholar
  41. 41.
    Zervos, M.J., M.S. Terpenning, D.R. Schaberg, P.M. Therasse, S.V. Medendorp, and C.A. Kauffman. 1987. High-level aminoglycoside-resistant enterococci. Colonization of nursing home and acute care hospital patients. Arch. Intern. Med. 147:159–194.CrossRefGoogle Scholar
  42. 42.
    Ziegler, E.J., J.A. McCutchan, J. Fierer, M.P. Glauser, J.C. Sadoff, H. Douglas, and A.I. Braude. 1982. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 307:1225–30.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1992

Authors and Affiliations

  • George L. Drusano

There are no affiliations available

Personalised recommendations